Federal Contractor Profile
Illinois Institute Of Technology
$61M obligated·136 awards·5 agencies·17 NAICS
Federal Contracts
Showing award actions 51–100 of 188 funded award actions, most recent first.
- Contracts with positive obligations
- 136
- Funded award actions shown
- 188
- Obligations shown
- $61M
- Awarding agencies
- 5
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of September 28, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Feb 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $21K |
| Feb 2, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $59K |
| Jan 3, 2024 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $39K |
| Sep 18, 2023 | Department of Health and Human ServicesNIH NCI | 75N91023F00001 | 541714 | BASE TITLE: PREVENT PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TASK ORDER TITLE: NICOTINE REDUCTION THERAPY USING THE HUMAN MONOCLONAL ANTIBODY ATI-1013 | $659K |
| Sep 14, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $1.4M |
| Aug 9, 2023 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $677K |
| Jun 30, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $202K |
| Jun 29, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $224K |
| Jun 29, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION | $22K |
| Mar 28, 2023 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $645K |
| Mar 23, 2023 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $309K |
| Mar 2, 2023 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $471K |
| Feb 22, 2023 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $419K |
| Nov 14, 2022 | Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGY | N6321523F0011 | 611310 | TUTION AND FEES FOR FALL 2021 | $301K |
| Sep 23, 2022 | Department of Health and Human ServicesNIH NCI | 75N91022F00001 | 541715 | CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS" | $3K |
| Sep 22, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION | $744K |
| Jul 15, 2022 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $123K |
| Jun 22, 2022 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $675K |
| May 15, 2022 | Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGY | N6321522F0010 | 611310 | TUITION AND FEES FOR 2022 SPRING SEMESTER | $341K |
| May 4, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $698K |
| Apr 26, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $207K |
| Mar 29, 2022 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $75K |
| Mar 28, 2022 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER | $291K |
| Feb 14, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $10K |
| Dec 14, 2021 | Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGY | N6321522F0003 | 611310 | TUTION AND FEES FOR FALL 2021 | $353K |
| Dec 10, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541714 | PRECLINICAL MICROBIOLOGICAL, SAFETY, TOXICOLOGY, AND PHARMACOKINETIC SERVICES | $1.9M |
| Dec 3, 2021 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $34K |
| Sep 30, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP) | $11 |
| Sep 29, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP) | $2K |
| Sep 7, 2021 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $702K |
| Aug 23, 2021 | Department of Health and Human ServicesNIH NCI | 75N91021F00001 | 541714 | EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER | $535K |
| Jul 19, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $1.3M |
| Jun 23, 2021 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $25K |
| Jun 9, 2021 | Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGY | N6321521F0401 | 611310 | TUITION AND FEES FOR SPRING SEMESTER AT ILLINOIS INSTITUTE OF TECHNOLOGY | $222K |
| Apr 27, 2021 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $118K |
| Feb 26, 2021 | Department of Health and Human ServicesNIH NCI | HHSN26100003 | 541690 | IGF::OT::IGF NEXT PRECLINICAL TOXICOLOGY&PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER PATIENTS, TO#3, EXPLORATORY STUDIES OF CCR4 CART CELLS | $239K |
| Feb 11, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $530K |
| Dec 8, 2020 | Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGY | N6321521F0400 | 611310 | TUTION AND FEES FOR FALL 2019 | $217K |
| Nov 30, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY21C0014 | 541380 | TECHNLOLOGY TRANSFER ASSAYS | $981K |
| Sep 24, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $324K |
| Sep 21, 2020 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541690 | SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG DEVELOPMENT) POP 09/23/2020-09/22/2021. | $589K |
| Sep 16, 2020 | Department of Health and Human ServicesNIH NCI | 75N91020F00002 | 541714 | COVID-19 RELATED STUDY INVOLVING DOGS | $598K |
| Sep 16, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $1.8M |
| Sep 15, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $153K |
| Sep 14, 2020 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $213K |
| Sep 2, 2020 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER | $430K |
| Aug 27, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00091 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020. | $7K |
| Aug 26, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | HHSN27100001 | 541712 | IGF::OT::IGF TASK ORDER AWARD FOR "NON-CLINICAL SAFETY ASSESSMENT OF SPIF TO SUPPORT CHRONIC GVHD INDICATION" TO IIT RESEARCH INSTITUTE | $95K |
| Jul 17, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00091 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020. | $81K |
| Jun 3, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00090 | 541712 | GLP 28 DAY TOXICITY STUDY OF ACT-1 WHEN APPLIED TOPICALLY TO EYES TWICE DAILY FOR 28 DAYS IN DOGS WITH A 14 DAY RECOVERY PERIOD. POP: 09/01/2019 TO 02/29/2020. | $85K |
Get Alerted Before Illinois Institute Of Technology's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free